Sunday, 21 July 2019

Roivant Sciences, Daiichi Sankyo enter into broad pipeline partnership

20 December 2018 | News

Under the terms of the agreement, Roivant will have the option to obtain exclusive licenses for certain development programs from Daiichi Sankyo on pre-specified terms contingent on phase of development

Roivant Sciences has announced that it has entered into collaboration with Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) to facilitate the out-licensing of investigational medicines.

Under the terms of the agreement, Roivant will have the option to obtain exclusive licenses for certain development programs from Daiichi Sankyo on pre-specified terms contingent on phase of development.

Dr. Mayukh Sukhatme, President of Roivant Pharma said, “It has been an honor and a pleasure for us to work with the entire Daiichi Sankyo team in the course of creating this partnership. I hope this can be a model for platform collaborations between Roivant and other innovative biopharmaceutical companies in the future. We look forward to accelerating the development of promising medicines from the impressive R&D engine at Daiichi Sankyo in the months and years ahead.”

Daiichi Sankyo has a wide range of compounds in development. Medicines that Roivant opts to license will be developed by new subsidiary companies within the Roivant family.

 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Blockchain offering a solution to the healthcare industry?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls